Time‐dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition

Patients with end‐stage kidney disease have an extremely high cardiovascular mortality rate, but there is a paradoxical relationship between lipid profile and survival in haemodialysis patients. To investigate whether inflammation/malnutrition confounds the associations between lipids and mortality, we studied a full lipid profile comprising of five clinically well‐established lipid parameters and its associations with mortality in a large, multinational European cohort with a median follow‐up >3 years.

[1]  P. Stenvinkel,et al.  Inflammation and Premature Ageing in Chronic Kidney Disease , 2020, Toxins.

[2]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[3]  C. Zoccali,et al.  Lipid management in patients with chronic kidney disease , 2018, Nature Reviews Nephrology.

[4]  Yuedong Wang,et al.  Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results , 2018, Journal of Lipid Research.

[5]  Connie M. Rhee,et al.  Inverse Association Between Serum Non–High‐Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis , 2018, Journal of the American Heart Association.

[6]  Jennifer G. Robinson,et al.  Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.

[7]  M. Landray,et al.  Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation , 2017, Kidney international.

[8]  F. Kronenberg,et al.  High cardiovascular event rates occur within the first weeks of starting hemodialysis , 2015, Kidney international.

[9]  Florian Kronenberg,et al.  Development and validation of a predictive mortality risk score from a European hemodialysis cohort , 2015, Kidney international.

[10]  K. Kalantar-Zadeh,et al.  Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  M. Tonelli,et al.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.

[12]  Yu-ming Chen,et al.  Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies , 2013, Lipids in Health and Disease.

[13]  D. Fliser,et al.  Uraemic dyslipidaemia revisited: role of high-density lipoprotein. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[15]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[16]  Florian Kronenberg,et al.  An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study , 2010, Nephron Clinical Practice.

[17]  B. Astor,et al.  Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. , 2010, Journal of the American Society of Nephrology : JASN.

[18]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[19]  R. Shamburek,et al.  Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. , 2010, Clinical chemistry.

[20]  B. Rutkowski,et al.  Temporal discrepancies in the association between the apoB/apoA‐I ratio and mortality in incident dialysis patients , 2009, Journal of internal medicine.

[21]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[22]  C. Wanner,et al.  A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. , 2008, Kidney international.

[23]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[24]  M. Landray,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials , 2007, Seminars in dialysis.

[25]  Ja‐Liang Lin,et al.  Fasting glucose levels in predicting 1-year all-cause mortality in patients who do not have diabetes and are on maintenance hemodialysis. , 2007, Journal of the American Society of Nephrology : JASN.

[26]  S. Anker,et al.  Risk factor paradox in wasting diseases , 2007, Current opinion in clinical nutrition and metabolic care.

[27]  K. Kalantar-Zadeh,et al.  Association between serum lipids and survival in hemodialysis patients and impact of race. , 2007, Journal of the American Society of Nephrology : JASN.

[28]  K. Kalantar-Zadeh,et al.  Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[29]  A. Kazory,et al.  Impact of malnutrition-inflammation on the association between homocysteine and mortality. , 2006, Kidney international.

[30]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[31]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[32]  P. Couture,et al.  Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. , 2004, Clinical biochemistry.

[33]  N. Powe,et al.  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. , 2004, JAMA.

[34]  H Steil,et al.  EuCliD® – A Medical Registry , 2004, Methods of Information in Medicine.

[35]  J. Frohlich,et al.  Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. , 2003, Clinical biochemistry.

[36]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[37]  S. Anker,et al.  The endotoxin-lipoprotein hypothesis , 2000, The Lancet.

[38]  K. Feingold,et al.  Lipoproteins: Are they important components of host defense? , 1997, Hepatology.

[39]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .